These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 26514998

  • 21. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
    Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK.
    PLoS One; 2019; 14(6):e0217964. PubMed ID: 31170246
    [Abstract] [Full Text] [Related]

  • 22. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ.
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [Abstract] [Full Text] [Related]

  • 23. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [Abstract] [Full Text] [Related]

  • 24. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
    Sweeney S, Ward Z, Platt L, Guinness L, Hickman M, Hope V, Maher L, Iversen J, Hutchinson SJ, Smith J, Ayres R, Hainey I, Vickerman P.
    Addiction; 2019 Mar; 114(3):560-570. PubMed ID: 30674091
    [Abstract] [Full Text] [Related]

  • 25. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M, Coretti S, Romano F, Kondili LA, Vella S, Cicchetti A.
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
    Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M.
    Transpl Int; 2013 May; 26(5):527-34. PubMed ID: 23517333
    [Abstract] [Full Text] [Related]

  • 27. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [Abstract] [Full Text] [Related]

  • 28. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.
    Bennett H, McEwan P, Sugrue D, Kalsekar A, Yuan Y.
    PLoS One; 2015 Jul; 10(5):e0125846. PubMed ID: 25938458
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S, Schaetti C, Bruggmann P, Negro F, Razavi H.
    Swiss Med Wkly; 2019 Mar 11; 149():w20026. PubMed ID: 30905063
    [Abstract] [Full Text] [Related]

  • 30. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J, He T, Hur C, Lopez-Olivo MA.
    Clin Gastroenterol Hepatol; 2017 Jun 11; 15(6):827-837.e8. PubMed ID: 27650326
    [Abstract] [Full Text] [Related]

  • 31. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT.
    BMC Infect Dis; 2019 Dec 02; 19(1):1019. PubMed ID: 31791253
    [Abstract] [Full Text] [Related]

  • 32. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena S, Hutchinson SJ, Mandal S, O'Moore E, Hickman M.
    Hepatology; 2016 Jun 02; 63(6):1796-808. PubMed ID: 26864802
    [Abstract] [Full Text] [Related]

  • 33. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M.
    Int J Drug Policy; 2022 Jan 02; 99():103458. PubMed ID: 34624732
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
    Gimeno-Ballester V, Mar J, San Miguel R.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jan 02; 16(2):285-94. PubMed ID: 26327360
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan 02; 17(1):77-87. PubMed ID: 24032626
    [Abstract] [Full Text] [Related]

  • 36. Hepatitis C: an economic evaluation of extended treatment with interferon.
    Shiell A, Brown S, Farrell GC.
    Med J Aust; 1999 Aug 16; 171(4):189-93. PubMed ID: 10494234
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK, Fleiz C, Burgos JL, Cepeda JA, McIntosh C, Garfein RS, Kiene SM, Brodine S, Strathdee SA, Martin NK.
    Addiction; 2021 Oct 16; 116(10):2734-2745. PubMed ID: 33620750
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.
    Am J Gastroenterol; 2004 Aug 16; 99(8):1490-6. PubMed ID: 15307866
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Cure S, Guerra I, Cammà C, Craxì A, Carosi G.
    J Med Econ; 2015 Aug 16; 18(9):678-90. PubMed ID: 25891129
    [Abstract] [Full Text] [Related]

  • 40. Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood.
    Greenaway E, Haines A, Ling SC, Krahn M.
    J Pediatr; 2021 Mar 16; 230():38-45.e2. PubMed ID: 32890583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.